Literature DB >> 22677986

Asbestos and SV40 in malignant pleural mesothelioma from a hyperendemic area of north-eastern Italy.

Manola Comar1, Nunzia Zanotta, Giuliano Pesel, Patrizia Visconti, Iva Maestri, Rosa Rinaldi, Sergio Crovella, Maurizio Cortale, Renata De Zotti, Massimo Bovenzi.   

Abstract

AIMS AND
BACKGROUND: Malignant mesothelioma is a fatal cancer of increasing incidence in north-eastern Italy. Together with asbestos, the polyomavirus SV40 was hypothesized to contribute to the onset of malignant mesothelioma. To investigate the putative role of SV40 in the individual susceptibility to asbestos-induced malignant mesothelioma, we conducted a molecular epidemiological study on a series of malignant mesothelioma patients from an area in north-eastern Italy hyperendemic for malignant pleural mesothelioma. METHODS AND STUDY
DESIGN: We collected 63 mesothelioma samples from incidence cases of patients diagnosed with malignant pleural mesothelioma in the period 2009-2010. DNA was extracted from patients' tissue biopsies using the BioRobot EZ1 Qiagen workstation. SV40 sequence detection and quantification was performed by specific real time PCR. The 74.6% of the 63 enrolled patients had a history of asbestos exposure. The epithelioid histotype was more prevalent in males (64.0%) and the mixed in females (61.5%) who showed significantly higher cancer co-morbidity (46.1% vs 12%, P = 0.005). SV40 was detected in 22% of MM tumors, with a low viral load. In SV40-positive patients, a threefold increased risk of asbestos exposure was observed, more evident in females (OR 4.32) than in males (OR 1.20).
CONCLUSIONS: Our findings indicate that a high prevalence of SV40 was present in malignant mesothelioma incident cases from an area hyperendemic for malignant mesothelioma in north-eastern Italy. Although asbestos is considered the main risk factor in malignant mesothelioma onset, a role for SV40 could be hypothesized.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22677986     DOI: 10.1177/030089161209800205

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  7 in total

1.  Current issues in malignant pleural mesothelioma evaluation and management.

Authors:  Jing Ai; James P Stevenson
Journal:  Oncologist       Date:  2014-07-24

2.  Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression.

Authors:  L Gutierrez-Sainz; P Cruz; S Martinez-Recio; O Higuera; M I Esteban-Rodriguez; F Arias-Lotto; R A Gonzalez; J De Castro-Carpeño
Journal:  Clin Transl Oncol       Date:  2021-04-10       Impact factor: 3.405

3.  Neutralizing and IgG antibodies against simian virus 40 in healthy pregnant women in Italy.

Authors:  Manola Comar; Connie Wong; Mauro Tognon; Janet S Butel
Journal:  PLoS One       Date:  2014-10-21       Impact factor: 3.240

Review 4.  The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma.

Authors:  Abdel-Ghani Azzouqa; James P Stevenson
Journal:  Onco Targets Ther       Date:  2016-11-25       Impact factor: 4.147

5.  NLRP1 polymorphisms in patients with asbestos-associated mesothelioma.

Authors:  Martina Girardelli; Iva Maestri; Rosa R Rinaldi; Mauro Tognon; Renzo Boldorini; Massimo Bovenzi; Sergio Crovella; Manola Comar
Journal:  Infect Agent Cancer       Date:  2012-10-02       Impact factor: 2.965

6.  Fanconi anemia patients are more susceptible to infection with tumor virus SV40.

Authors:  Manola Comar; Daniela De Rocco; Enrico Cappelli; Nunzia Zanotta; Roberta Bottega; Johanna Svahn; Piero Farruggia; Aldo Misuraca; Fabio Corsolini; Carlo Dufour; Anna Savoia
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

7.  Increased levels of C-C chemokine RANTES in asbestos exposed workers and in malignant mesothelioma patients from an hyperendemic area.

Authors:  Manola Comar; Nunzia Zanotta; Alessandra Bonotti; Mauro Tognon; Corrado Negro; Alfonso Cristaudo; Massimo Bovenzi
Journal:  PLoS One       Date:  2014-08-27       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.